TMRW Life Sciences, Inc.

Founded in 2018 and based in New York, TMRW Life Sciences, Inc. is a femtech company that develops TMRW ivfOS, an integrated platform which uses radio-frequency identification for preserving, managing, identifying, and storing fertility cells in cryo-temperature. The company was co-founded by Alan Murray, Jeffrey Port, and Joshua Abram. TMRW Life Sciences has raised a total of USD 153.

5 million in funding over 4 rounds and is backed by investors including 5AM Ventures, GV, and Transformation Capital which led the Series C funding round of USD 105 million in July 2021. TMRW is now being used by fertility clinics in the United States, including Vios Fertility Institute, Conceptions Reproductive Associates of Colorado, San Diego Fertility Center, Boston IVF, and Colorado Center for Reproductive Medicine (CCRM). TMRW Life Sciences provides an automated platform for the management, identification, and storage of frozen human eggs and embryos at the center of every IVF procedure. The company replaces the current analog system with integrated software and robotics, 24/7 remote monitoring, and a complete digital chain of custody for all frozen eggs and embryos in the IVF lab.

TMRW’s software eliminates error-prone manual tasks in the lab that put specimens at risk, allowing embryologists to focus on the more skilled and technical aspects of their work. TMRW Life Sciences plans to accelerate its global expansion, advance cutting-edge product innovation, develop consumer awareness of the platform, and support future business development opportunities.